Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides has reported that oral administration of FluCide anti-influenza drug candidates caused lung viral load decrease comparable to IV Administration and superior to Oseltamivir, in an animal model.
Subscribe to our email newsletter
According to the study data, two different anti-influenza drug candidates tested in Oral vs. IV comparison showed similar results that indicated strong oral effectiveness and demonstrated superior animal protection compared to oseltamivir (Tamiflu).
NanoViricides chairman and president Anil Diwan said, "We can easily increase the effectiveness of our drugs by increasing the oral dosage."
The lung viral load measured at 108 hours post-infection (hpi) showed that one of the orally administered FluCide drug candidates resulted in 1.30 log reduction (or 20X reduction) in lung viral load and matched the viral load reduction on the same drug candidate given as an IV injection.
Another drug candidate resulted in 1.23 log viral load reduction when given orally and 1.31 log viral load reduction when given as an injectable, according to the company.
As compared to negative controls, oseltamivir (Tamiflu, given orally at 40mg/kg/d) resulted in only 0.6 log viral load reduction (or only 4X reduction).